Navigation Links
PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
Date:12/9/2010

ANNAPOLIS, Md., Dec. 9, 2010 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that the United States Food and Drug Administration (FDA) has provided formal consent for PharmAthene to reinitiate clinical testing of its anthrax anti-toxin, Valortim®, after lifting the partial clinical hold placed on the program in late 2009.

"We're very pleased to resume clinical testing of Valortim®," remarked Dr. Thomas Fuerst, Senior Vice President and Chief Scientific Officer.  "The accumulating data suggest that Valortim® may have unique characteristics, which could position it as a leading candidate for future procurement in the nation's biodefense stockpile.  A presumed different mechanism of action, relative to other anthrax monoclonal antibodies and encouraging efficacy data in animal studies at low doses, suggest that Valortim® may offer important advantages in the treatment of symptomatic anthrax infection."

Dr. Fuerst continued, "We have proposed moving forward with a Phase I intravenous dose-escalation study of Valortim®, which is expected to commence in the next several weeks.  We look forward to resuming clinical testing of this important anthrax anti-toxin candidate, which we hope one day will offer improved protection for our nation's citizens, both at home and on the battlefield."

Valortim® is a fully human anti-toxin monoclonal antibody being developed for the prevention and treatment of inhalational anthrax.  Animal studies suggest that Valortim® has the potential to provide protection against anthrax infection when administered prophylactically (prior to the emergence of symptoms of anthrax infection) and also may increase survival when administered therapeutically (once symptoms become evident).

The Valortim® project has been funded in whole or in part with Federal f
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
2. PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000
3. PharmAthene Announces Pricing of $15 Million Public Offering
4. PharmAthene Announces Proposed Common Stock Offering
5. PharmAthene Announces $3.9 Million Registered Direct Offering
6. PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
7. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
8. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
9. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
10. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
11. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Spartan Bioscience announced today that Health Canada has ... detects CYP2C19 genetic mutations in less than 60 minutes ... CYP2C19 System is the first near-patient DNA test for ... to the system’s ease of use, Health Canada has ... such as doctors, nurses, pharmacists, and laboratory technicians, in ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
(Date:10/30/2014)... (Oct. 29, 2014) – The severe flooding that devastated ... been less destructive if the bridges, roads and other ... new study from the University of Colorado Denver. , ... infrastructure," said Jimmy Kim, PhD, associate professor of structural ... Applied Science and lead author the study. "There is ...
(Date:10/27/2014)... and TORONTO , Oct. 27, ... ) (OTCQB: GNBT) today announced two presentations demonstrating ... by its novel proprietary cancer immunotherapeutic AE37 vaccine ... cancer patients. The AE37 cancer vaccine is being ... Inc. ( www.antigenexpress.com ). The presentations are being ...
Breaking Biology Technology:Health Canada approves first near-patient DNA test for personalized medicine 2Health Canada approves first near-patient DNA test for personalized medicine 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2CU Denver study says upgrading infrastructure could reduce flood damage 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4
... When Hurricane Dennis reached landfall in the Florida ... surprising a development. Weather Central Inc. , a ... almost the exact location two days earlier. , ,On ... a service used by more than 100 television stations ...
... unexpectedly, this sudden accident incubates a branding process, which can ... gives birth to an extreme name identity, whereupon a major ... not stirred -- and that's how we refer to today's ... the secrets of the various branding tricks and become aware ...
... by thousands of U.S. companies since the 1970s, it ... in more than 35 states have introduced legislation restricting ... effective cost-cutting tool has begun to soar. Early in ... outsourcing, it was often viewed as a way ...
Cached Biology Technology:Accidental naming 2Accidental naming 3Accidental naming 4Consider the legal issues before outsourcing offshore 2Consider the legal issues before outsourcing offshore 3Consider the legal issues before outsourcing offshore 4Consider the legal issues before outsourcing offshore 5
(Date:10/29/2014)... factors, both genetic and environmental, have been blamed ... schizophrenia. Some, such as a family history of ... with Toxoplasma gondii , a parasite transmitted ... still viewed with skepticism. , A new study ... epidemiology at the University of Pennsylvania,s School of ...
(Date:10/29/2014)... all the rage. Thousands of scientists worldwide are conducting ... titanium dioxide nanoparticles from sun creams can get through ... from electronic products are as hazardous for the lungs ... food can get into the blood via the intestinal ... are flowing – and the number of scientific projects ...
(Date:10/29/2014)... in German . ... and Peter Schlögelhofer at the Max F. Perutz Laboratories ... University of Vienna dived into the process of meiosis ... display an inversion of the standard meiotic phases. The ... Nature Communications . , Meiosis is the two-step ...
Breaking Biology News(10 mins):Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3Meiotic cell division 'the other way round' 2
... Damselfish are killing head corals and adding stress ... poor condition from global climate change, coral diseases, hurricanes, ... favorite homestead, will take the pressure off the other ... online journal PLoS ONE . The small, ...
... miles of the nation,s infrastructure of water ... of its useful life, but the mostly ... attention because of this "invisibility," said Sunil ... and environmental engineering (CEE). http://www.cee.vt.edu/index.php?do=view&content=0&apps=2&level=2&id=17&pid=b024555fa7f439a27509de488a7b5749 ...
... most likely to occur on Sunday, in less than 6 ... wearing black and white bathing suits, a first of its ... analyzed statistics from shark attacks that occurred in Florida,s Volusia ... 1956 and 2008. They also spent a year observing people ...
Cached Biology News:Distressed damsels stress coral reefs 2Efforts underway at Virginia Tech to address deterioration of nation's water pipes 2Case study analyzes why, where and when of leading shark attack site 2Case study analyzes why, where and when of leading shark attack site 3
... Clarin represents the state-of-the-art in ... for the permanent preservation of immunohistochemical ... (DAB), Vega Red, New Fuchsin, and ... substrates on tissue sections. Clarin can ...
... Gene Inspector can perform many sophisticated DNA analysis ... much more than just another sequence analysis product. ... suite of analyses to be performed each time ... custom style sheets which specify exactly how your ...
... columns is a well-known separation technique in ... are in DNA/RNA extraction in microbiology, viral ... in chemical or analytical laboratories. ,This ... series instruments for smaller scales. The extraction ...
... is a revolutionary new application for ... a novel interface, Expression makes complex ... simple. Expression uses the very latest ... in the way sequences are analysed. ...
Biology Products: